The gut-liver axis is essential for disease progression in the Mdr2-/- mouse model of primary sclerosing cholangitis

被引：0
|
作者：
Liao, L. [1 ,2 ]
Schneider, K. M. [1 ]
Frissen, M. [1 ]
Strowig, T. [3 ]
Marschall, H. -U. [4 ]
Wahlstroem, A. [4 ]
Eric, G. [3 ]
Mohs, A. [1 ]
Jin, P. [1 ]
Jung, J. [1 ]
Reissing, J. [1 ]
Sun, H. [1 ]
Elfers, C. [1 ]
Bieghs, V. [1 ]
Cubero, F. J. [5 ]
Trautwein, C. [1 ]
机构：
[1] Univ Hosp, Dept Internal Med 3, Aachen, Germany
[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Pain Management, Shanghai, Peoples R China
[3] Helmholtz Ctr Infect Res, Braunschweig, Germany
[4] Univ Gothenburg, Wallenberg Lab, Gothenburg, Sweden
[5] Univ Complutense Madrid, Sch Med, Dept Immunol, Madrid, Spain
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PS-004
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [31] Primary sclerosing cholangitis: 50 years of a gut-liver relationship and still no love?
    Karlsen, Tom H.
    GUT, 2016, 65 (10) : 1579 - 1581
  • [32] MANIPULATION OF THE MIR-16/FGF-1 AXIS REDUCES PROFIBROTIC, PROLIFERATIVE, AND INFLAMMATORY PHENOTYPES IN THE MDR2-/- MOUSE MODEL OF PRIMARY SCLEROSING CHOLANGITIS (PSC)
    O'Brien, April
    White, Tori
    Kyritsi, Konstantina
    Francis, Heather L.
    Zhou, Tianhao
    Chakraborty, Sanjukta
    Meng, Fanyin
    Alpini, Gianfranco
    Glaser, Shannon S.
    HEPATOLOGY, 2020, 72 : 309A - 310A
  • [33] Death Receptor Deficiency Augments Ductular Reaction and Hepatic Fibrosis in the Mdr2-/- Mouse Model of Sclerosing Cholangitis
    Krishnan, Anuradha
    Katsumi, Tomohiro
    Guicciardi, Maria Eugenia
    Bronk, Steven F.
    Azad, Adiba
    Gores, Gregory J.
    HEPATOLOGY, 2018, 68 : 829A - 830A
  • [34] Manipulation of the gut-liver axis by interruption of bile acid recirculation: an option for the treatment of sclerosing cholangitis?
    Jahn, Daniel
    Marzioni, Marco
    Geier, Andreas
    GUT, 2018, 67 (09) : 1565 - 1567
  • [35] Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis via immunomodulatory effects
    Fuchs, Claudia D.
    Dixon, Emmanuel D.
    Hendrikx, Tim
    Mlitz, Veronika
    Wahlstrom, Annika
    Stahlman, Marcus
    Scharnagl, Hubert
    Stojakovic, Tatjana
    Binder, Christoph J.
    Marschall, Hanns-Ulrich
    Trauner, Michael
    HEPATOLOGY COMMUNICATIONS, 2022, 6 (09) : 2368 - 2378
  • [36] Comparative potential of soybean lecithin and ursodeoxycholic acid against the progression of liver disease in the Mdr2-/- mouse model
    Martel, M
    St-Hilaire, W
    Tuchweber, B
    Bouchard, G
    GASTROENTEROLOGY, 2005, 128 (04) : A260 - A260
  • [37] COMBINATION TREATMENTS OF AN IBAT INHIBITOR AND VARIOUS PPAR ISOFORM AGONISTS INDUCE DISTINCT CHANGES IN LIVER BIOCHEMISTRIES IN THE MDR2-/-MOUSE MODEL OF SCLEROSING CHOLANGITIS
    Kudira, Ramesh
    Pfuhler, Liva
    Mullen, Mary
    Whyte, Senyo
    Bariya, Priya
    Zhang, Wujuan
    Setchell, Kenneth D. R.
    Kostrub, Cory
    Vig, Pamela
    Miethke, Alexander
    HEPATOLOGY, 2022, 76 : S1509 - S1509
  • [38] Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study
    Blesl, Andreas
    Juengst, Christoph
    Lammert, Frank
    Fauler, Guenter
    Rainer, Florian
    Leber, Bettina
    Feldbacher, Nicole
    Stromberger, Silvia
    Wildburger, Renate
    Spindelboeck, Walter
    Fickert, Peter
    Horvath, Angela
    Stadlbauer, Vanessa
    NUTRIENTS, 2020, 12 (09) : 1 - 27
  • [39] While small cholangiocytes contribute to liver fibrosis by enhanced phenotype transition, large cholangiocytes trigger liver fibrosis by enhanced senescence in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC)
    Zhou, Tianhao
    Wu, Nan
    Francis, Heather L.
    Venter, Julie
    RamosLorenzo, Sugeily
    McDaniel, Kelly
    Kyritsi, Tina
    Ehrlich, Laurent
    Glaser, Shannon S.
    Meng, Fanyin
    Alpini, Gianfranco
    HEPATOLOGY, 2016, 64 : 161A - 161A
  • [40] Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
    Nair, Bhagyalakshmi
    Kamath, Adithya Jayaprakash
    Tergaonkar, Vinay
    Sethi, Gautam
    Nath, Lekshmi R.
    LIFE SCIENCES, 2024, 351
12345